imidazole-4-carboxamide

10/01/1984 - "Epigenetic effects of the methylating agent 5-(3-methyl-1-triazeno) imidazole-4-carboxamide in human melanoma cells."
01/01/1974 - "Effect of imidazole-4-carboxamide, 5-(3,3-dimethyl-1-triazeno) on immunity in patients with malignant melanoma."
01/01/1971 - "Clinical evaluation of 5-(3,3-dimethyl-1-triazeno) imidazole-4-carboxamide in malignant melanoma and other neoplasms: comparison of twice-weekly and daily administration schedules."
01/01/2022 - "The Fairy Chemical Imidazole-4-carboxamide Inhibits the Expression of Axl, PD-L1, and PD-L2 and Improves Response to Cisplatin in Melanoma."
01/01/2019 - "5-(3,3-Dimethyle-1-Triazeno) Imidazole-4-Carboxamide and Interleukin-2 Adjuvant Therapy in Resected High-Risk Primary and Regionally Metastatic Melanoma."

02/01/1976 - "Letter: Disseminated intravascular coagulation syndrome with metastatic melanoma: Remission after treatment with 5-(3,3-dimethyl-1-triazeno) imidazole-4-carboxamide (DTIC)."

01/01/1971 - "Clinical evaluation of 5-(3,3-dimethyl-1-triazeno) imidazole-4-carboxamide in malignant melanoma and other neoplasms: comparison of twice-weekly and daily administration schedules."
01/01/2022 - "Two series of novel 4-phenoxypyridine derivatives containing imidazole-4-carboxamide and 4-methyl-5-oxo-4,5-dihydro-1,2,4-triazole-3-carboxamide moieties were synthesized and evaluated for their in vitro inhibitory activities against c-Met kinase and antiproliferative activities against MKN-45, A549 and H460 cancer cell lines. "
09/01/1980 - "The cancer chemotherapeutic drug, 5-(3,3-dimethyl-1-triazeno) imidazole-4-carboxamide (DIC, DTIC, NSC-45388), is metabolised in rats to a structurally related product which was detected by thin-layer chromatography. "
09/01/1972 - "Hexamethylmelamine (NSC-13875) alone and in combination with 5-(3, 3-dimethyl-1-triazeno) imidazole-4-carboxamide (NSC-45388) in the treatment of advanced cancer."
01/01/2022 - "These observations point to the fairy chemical imidazole-4-carboxamide as a promising coadjuvant therapy with cisplatin in patients with cancer."

01/01/1976 - "Antigenic changes of L5178Y lymphoma after treatment with 5-(3,3-dimethyl-1-triazeno) imidazole-4-carboxamide in vivo."
07/01/1979 - "Changes of the immunogenic properties of K36 lymphoma treated in vivo with 5(3,3-dimethyl-1-triazeno) imidazole-4-carboxamide (DTIC)."
05/15/1977 - "Cell kinetics and immunoegenicity of lymphoma cells treated with 5-(3,3-dimethyl-1-triazeno) imidazole-4-carboxamide (DIC) in vivo."

12/31/1993 - "Mouse leukemia, L1210, strongly enhances its immunogenicity following in vivo treatment with 5-(3-3'-dimethyl-1-triazeno) imidazole-4-carboxamide (DTIC). "
06/01/1971 - "Enhanced response of leukemia (L1210) mice to combination chemotherapy with 5-(3,3-dimethyl-1-triazeno) imidazole-4-carboxamide (NSC-45388) and 5-fluorouracil (NSC-19893)."